Late Breaking Science – A clinical study published or accepted for publication in Q1 Cardiology Journal during the year 2024
Myocardial and Pericardial Diseases
Pacing and Electrophysiology
Rehabilitation, Prevention and Risk Factors / Epidemiology / Pharmacotherapy and Cardiac Pharmacology
With the submission of an abstract, the first author (presenting author):
Accepts responsibility for the accuracy of the submitted abstract.
Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.
States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
Gives permission for the abstract, when selected for presentation (oral or poster), to be published.
Encore abstracts will be accepted.
Submitted abstracts cannot withdrawn after the official submission deadline.
In order to be considered, an abstract should respect the following guidelines:
The abstract must be submitted in good English.
The Scientific Committee reserves the right to reject those abstracts, which are presented in poor English, or may request an immediate revision by the presenter.
Abstract titles should be brief and should reflect the content of the abstract.
Commercial names may not be used in the abstract title.
No more than 10 authors can be listed. Only institutional affiliations, cities and countries should follow.
Abstracts on “trials in progress” can be submitted and will be considered for oral or poster presentation as long as they contain at least some preliminary and presentable results.
The decision regarding inclusion in the program and type of presentation will be decided by the Scientific Program Committee.
Abstracts should be organized under the headings:
Introduction -> Material and method -> Results and discussion -> Conclusion
The online abstract submission procedure will not accept abstracts that exceed 300 words (body of the abstract).
Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.
Supplementary data or appendices will not be accepted.
Figures or photographs are allowed. Symbols and structures of drugs are allowed and should be drawn in black.
Only the submitting author will receive a confirmation/abstract number by e-mail from the IHS2024 Secretariat within 48 hours of submission. This confirmation of abstract receipt is NOT a notice of acceptance.
Only abstracts submitted online can be accepted. Abstracts submitted on paper or by e-mail attachment will not be considered.
The Scientific Committee will make the selection of abstracts for oral and poster presentations on March 2024.
If a selected author cannot attend, the presenting author should assign a replacement.
The following presentation formats are applicable for IHS2024: Oral presentation or Poster presentation.
Abstracts may be submitted for oral, or poster presentations. The Scientific Committee will determine whether abstracts will be accepted based on blind review. They will endeavor to schedule abstracts according to authors’ preferences but reserve the right to decide on the final form of presentation.
If you do not receive any confirmation within 48 hours, please contact the Conference Secretariat within one week following the submission of the abstract.
Submitting an abstract for IHS2024 does not constitute registration for the meeting. All abstract submitters must complete their registration and payment to the IHS2024 meeting by April 19th, in order to be considered as part of the scientific program.